Group 1 - The company is currently focused on completing the drug review response work and is working overtime to prepare supplementary materials, but cannot determine the exact response time [2] - The company is developing two anti-tumor targeted original new drugs, CSCJC3456 and CSCJC4523 [2] - There is a strong expectation from patients for the drugs to be approved and to contribute to public health, raising questions about the company's ability to meet market demand post-approval [2]